FIELD: medicine.
SUBSTANCE: invention relates to medicine namely, to pulmonology, allergology and physiotherapy, and can be used for medical rehabilitation of patients with partially controlled mild bronchial asthma. To do this, basic inhalation therapy is given with the mometasone furoate drug product of 400 mcg for 1 inhalation once a day. EHF-therapy is simultaneously performed. At the same time, biologically active points of acupuncture VC 21 (huan-ji), G14 (he-gu), VG 14(13) (da-zhui), VG10(9) (ling-tai), VG9(8) (zhi-yang) are affected by electromagnetic radiation of millimeter range.
EFFECT: method provides an improvement of the parameters of external respiration, reduction of the terms for achieving complete control over the disease, immunomodulating effect with normalization of the cellular immunity system.
3 cl, 2 tbl, 1 dwg, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR TREATING BRONCHIAL ASTHMA | 2020 |
|
RU2747677C1 |
METHOD FOR REGENERATIVE TREATMENT OF PATIENTS WITH BRONCHIAL ASTHMA AND OBESITY | 2016 |
|
RU2622610C1 |
METHOD OF TREATMENT OF BRONCHIAL ASTHMA | 2017 |
|
RU2652752C1 |
METHOD FOR IMMUNODEFICIENT CONDITIONS CORRECTION BY "ALLOPLANT" BIOMATERIAL | 2016 |
|
RU2634631C1 |
METHOD OF REHABILITATION OF PATIENTS WITH BRONCHIAL ASTHMA | 2018 |
|
RU2717708C1 |
METHOD FOR ASSESSING AND PREDICTING THE RISK OF DEVELOPING SMALL AIRWAY DYSFUNCTION IN PATIENTS WITH BRONCHIAL ASTHMA ASSOCIATED WITH OBESITY | 2021 |
|
RU2778070C1 |
METHOD FOR ASSESSING THE DEGREE OF RISK OF MAJOR RESPIRATORY DYSFUNCTION DEVELOPMENT IN PATIENTS WITH EARLY STAGES OF BRONCHIAL ASTHMA | 2020 |
|
RU2741858C1 |
METHOD OF PREDICTING RISK OF DEVELOPMENT OF THERAPEUTIC RESISTANCE IN PATIENTS WITH BRONCHIAL ASTHMA | 2010 |
|
RU2433401C1 |
METHOD OF DETERMINING BRONCHIAL ASTHMA CONTROL RATIO | 2010 |
|
RU2440035C2 |
METHOD FOR PREDICTION OF RISK OF UNCONTROLLED BRONCHIAL ASTHMA | 2014 |
|
RU2559905C1 |
Authors
Dates
2018-05-28—Published
2017-02-27—Filed